{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:34:16Z","timestamp":1793385256926,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105207","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:45:29Z","timestamp":1770943529000},"page":"105207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2979-6495","authenticated-orcid":false,"given":"Francesca","family":"Carosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-7282","authenticated-orcid":false,"given":"Daria Maria","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Sgarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fermi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Querzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Romaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mercante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Tarsitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Lauriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2026.105207_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181356","article-title":"ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC","volume":"12","author":"Alvarado","year":"2017","journal-title":"PLoS One"},{"issue":"27","key":"10.1016\/j.critrevonc.2026.105207_bib2","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105207_bib3","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1200\/JCO.2005.07.119","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105207_bib4","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1002\/cncr.31651","article-title":"Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives","volume":"124","author":"Bauman","year":"2018","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105207_bib5","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1200\/JCO.2005.06.411","article-title":"Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial","volume":"23","author":"Bentzen","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"7572","key":"10.1016\/j.critrevonc.2026.105207_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature14969","article-title":"The genomic landscape of response to EGFR blockade in colorectal cancer","volume":"526","author":"Bertotti","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105207_bib7","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/hed.28152","article-title":"Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","volume":"47","author":"Bhatia","year":"2025","journal-title":"Head. Neck"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105207_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1634\/theoncologist.2013-0013","article-title":"Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance","volume":"18","author":"Boeckx","year":"2013","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105207_bib9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105207_bib11","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1158\/0008-5472.CAN-14-0294","article-title":"AXL mediates resistance to cetuximab therapy","volume":"74","author":"Brand","year":"2014","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105207_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1078-0432.CCR-05-1671","article-title":"Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo","volume":"12","author":"Bruzzese","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0202-2","article-title":"Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer","volume":"51","author":"Byeon","year":"2019","journal-title":"Exp. Mol. Med"},{"issue":"7536","key":"10.1016\/j.critrevonc.2026.105207_bib14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105207_bib15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.37349\/etat.2021.00062","article-title":"Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies","volume":"2","author":"Cavalieri","year":"2021","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.critrevonc.2026.105207_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1758-3284-3-11","article-title":"The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"3","author":"Chau","year":"2011","journal-title":"Head. Neck Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105207_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bjc.6604875","article-title":"Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas","volume":"100","author":"Dahse","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105207_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/onc.2016.216","article-title":"FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR\/ERK signaling","volume":"36","author":"Daly","year":"2017","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105207_bib19","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-11-2825","article-title":"A phase II study of lapatinib in recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"18","author":"de Souza","year":"2012","journal-title":"Clin. Cancer Res"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105207_bib20","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1158\/1078-0432.CCR-18-3453","article-title":"Molecular and clinical activity of CDX-3379, an anti-ErbB3 monoclonal antibody, in head and neck squamous cell carcinoma patients","volume":"25","author":"Duvvuri","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105207_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110899","article-title":"DAHANCA. DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck","volume":"208","author":"Eriksen","year":"2025","journal-title":"Radio. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40425-019-0550-z","article-title":"Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma","volume":"7","author":"Espinosa-Cotton","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105207_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.oraloncology.2019.02.026","article-title":"PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma","volume":"91","author":"Eze","year":"2019","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105207_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.2501","article-title":"Safety, pharmacokinetics (PK), pharmacodynamics (Pd), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted therapies","volume":"34","author":"Falchook","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105207_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fonc.2016.00232","article-title":"Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study)","volume":"6","author":"Fayette","year":"2016","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105207_bib26","article-title":"Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, open-label study","volume":"43","author":"Fei","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105207_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/CCO.0000000000001022","article-title":"The potential roles of antibody-drug conjugates in head and neck squamous cell carcinoma","volume":"36","author":"Filippini","year":"2024","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105207_bib28","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.63678","article-title":"EGFR transactivates RON to drive oncogenic crosstalk","volume":"10","author":"Franco Nitta","year":"2021","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1517\/14728222.2011.541440","article-title":"EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy","volume":"15","author":"Freudlsperger","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.critrevonc.2026.105207_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/OTT.S68235","article-title":"Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines","volume":"8","author":"Fumagalli","year":"2015","journal-title":"Onco Targets Ther."},{"issue":"10166","key":"10.1016\/j.critrevonc.2026.105207_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105207_bib32","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/annonc\/mdz388","article-title":"Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial","volume":"30","author":"Guo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105207_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/cancers10100355","article-title":"A novel role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy","volume":"10","author":"Gelfo","year":"2018","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105207_bib34","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.3390\/ijms21176009","article-title":"Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies","volume":"21","author":"Gelfo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105207_bib35","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2009-0058","article-title":"Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma","volume":"14","author":"Hama","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105207_bib36","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1016\/j.annonc.2023.09.2006","article-title":"860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent\/metastatic nasopharyngeal carcinoma","volume":"34","author":"Han","year":"2023","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105207_bib37","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.ejca.2012.11.023","article-title":"Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease","volume":"49","author":"Harrington","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105207_bib38","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1200\/JCO.2005.07.120","article-title":"Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck","volume":"23","author":"Herbst","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105207_bib39","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-0100","article-title":"Phase I clinical trial of the bifunctional EGFR\/TGF-\u03b2 fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumors","author":"Hernando-Calvo","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105207_bib40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccell.2020.12.007","article-title":"Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma","volume":"39","author":"Huang","year":"2021","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105207_bib41","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/cncr.30256","article-title":"Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin\/5-fluorouracil or carboplatin\/paclitaxel for first-line treatment of recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"122","author":"Jimeno","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105207_bib42","first-page":"454","article-title":"TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma","volume":"10","author":"Ju","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105207_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ctrv.2017.01.003","article-title":"Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck","volume":"54","author":"Juergens","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"6478","key":"10.1016\/j.critrevonc.2026.105207_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105207_bib45","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2005.04.8306","article-title":"Epidermal growth factor receptor biology in head and neck cancer","volume":"24","author":"Kalyankrishna","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.oraloncology.2014.08.014","article-title":"Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma","volume":"51","author":"Khattri","year":"2015","journal-title":"Oral. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105207_bib47","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1158\/1078-0432.CCR-21-3025","article-title":"Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): a phase II study with biomarker analysis","volume":"28","author":"Kao","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105207_bib48","doi-asserted-by":"crossref","DOI":"10.4322\/acr.2021.251","article-title":"Study of EGFR mutations in head and neck squamous cell carcinomas","volume":"11","author":"Kaur","year":"2021","journal-title":"Autops Case Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105207_bib49","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1158\/1078-0432.CCR-14-1756","article-title":"Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105207_bib50","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4143\/crt.2024.1195","article-title":"Differential efficacy of alpelisib by PIK3CA mutation site in head and neck squamous cell carcinoma: an analysis from the KCSG HN 15-16 TRIUMPH trial","volume":"57","author":"Kim","year":"2025","journal-title":"Cancer Res Treat."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105207_bib51","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1349-7006.2007.00510.x","article-title":"Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor","volume":"98","author":"Kimura","year":"2007","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105207_bib52","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-12-4047","article-title":"Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer","volume":"73","author":"Keysar","year":"2013","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105207_bib53","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/mc.22526","article-title":"A. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition","volume":"56","author":"Kulsum","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.critrevonc.2026.105207_bib54","doi-asserted-by":"crossref","first-page":"S1557","DOI":"10.1016\/j.annonc.2024.10.434","article-title":"411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent\/metastatic (r\/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial","volume":"35","author":"Le Tourneau","year":"2024","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105207_bib55","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1158\/1078-0432.CCR-04-2029","article-title":"Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck","volume":"11","author":"Lee","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105207_bib56","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/cancers12051073","article-title":"LINC00963 promotes cancer stemness, metastasis, and drug resistance in head and neck carcinomas via ABCB5 regulation","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105207_bib57","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-0459","article-title":"BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC","volume":"78","author":"Leonard","year":"2018","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105207_bib58","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2217\/14796694.3.4.441","article-title":"Ron-receptor tyrosine kinase in tumorigenesis and metastasis","volume":"3","author":"Leonis","year":"2007","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41392-022-01297-0","article-title":"Targeted therapy for head and neck cancer: signaling pathways and clinical studies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2005.08.034","article-title":"Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma","volume":"42","author":"Loeffler-Ragg","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105207_bib61","doi-asserted-by":"crossref","first-page":"8240","DOI":"10.1158\/0008-5472.CAN-07-0589","article-title":"Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab","volume":"67","author":"Lu","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105207_bib62","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(15)70124-5","article-title":"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial","volume":"16","author":"Machiels","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7911","key":"10.1016\/j.critrevonc.2026.105207_bib63","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41586-022-04718-w","article-title":"Extricating human tumour immune alterations from tissue inflammation","volume":"605","author":"Mair","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105207_bib64","doi-asserted-by":"crossref","first-page":"294","DOI":"10.15252\/emmm.201708076","article-title":"An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors","volume":"10","author":"Mancini","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"10166","key":"10.1016\/j.critrevonc.2026.105207_bib65","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105207_bib66","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1470-2045(14)71198-2","article-title":"Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial","volume":"16","author":"Mes\u00eda","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105207_bib67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/crst.crst_364_22","article-title":"Demographic profile and risk factors of head-and-neck squamous cell carcinoma in west Tamil Nadu: A cross-sectional observational study","volume":"6","author":"Michaelraj","year":"2023","journal-title":"Cancer Res. Stat. Treat."},{"key":"10.1016\/j.critrevonc.2026.105207_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/709678","article-title":"Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: a Hellenic Cooperative Oncology Group Study","volume":"2010","author":"Murray","year":"2010","journal-title":"J. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105207_bib69","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ejca.2006.09.025","article-title":"EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil","volume":"43","author":"Na","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105207_bib70","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1158\/1078-0432.CCR-23-2303","article-title":"A phase I study of the CDK4\/6 inhibitor palbociclib in combination with cetuximab and radiotherapy for locally advanced head and neck squamous cell carcinoma","volume":"30","author":"Ngamphaiboon","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"7873","key":"10.1016\/j.critrevonc.2026.105207_bib71","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105207_bib72","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hed.23922","article-title":"Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma","volume":"38","author":"Papadimitrakopoulou","year":"2016","journal-title":"Head. Neck"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105207_bib73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/HAB-2010-0232","article-title":"IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab","volume":"19","author":"Patel","year":"2010","journal-title":"Hum. Antibodies"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105207_bib74","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10637-016-0367-2","article-title":"Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)","volume":"34","author":"Prawira","year":"2016","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105207_bib75","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-06-2773","article-title":"A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo","volume":"67","author":"Rajput","year":"2007","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105207_bib76","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-13-2721","article-title":"RAS\/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma","volume":"20","author":"Rampias","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105207_bib77","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105207_bib78","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jnci\/90.11.824","article-title":"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival","volume":"90","author":"Rubin Grandis","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105207_bib79","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105207_bib80","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/CCO.0000000000000730","article-title":"The role of the tumor matrix environment in progression of head and neck cancer","volume":"33","author":"Saint","year":"2021","journal-title":"Curr. Opin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105207_bib81","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1158\/1078-0432.CCR-10-2120","article-title":"Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro","volume":"17","author":"Sano","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105207_bib82","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.oraloncology.2011.02.009","article-title":"Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer","volume":"47","author":"Sayed","year":"2011","journal-title":"Oral. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105207_bib83","first-page":"1963","article-title":"HNSCC cells resistant to EGFR pathway inhibitors are hypermutated and sensitive to DNA damaging substances","volume":"6","author":"Schulz","year":"2016","journal-title":"Am. J. Cancer Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105207_bib84","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdu216","article-title":"A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"25","author":"Seiwert","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105207_bib85","doi-asserted-by":"crossref","first-page":"508","DOI":"10.18632\/oncotarget.28747","article-title":"Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: insights into RTK dependent and independent mechanisms","volume":"16","author":"Shyamsunder","year":"2025","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105207_bib86","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1535-7163.MCT-14-0580","article-title":"Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy","volume":"14","author":"Singha","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105207_bib87","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-06-0913","article-title":"Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting","volume":"12","author":"Sok","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105207_bib88","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"18","author":"Souli\u00e8res","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105207_bib89","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1158\/1078-0432.CCR-17-2644","article-title":"Molecular alterations and buparlisib efficacy in patients with squamous cell carcinoma of the head and neck: biomarker analysis from BERIL-1","volume":"24","author":"Souli\u00e8res","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105207_bib90","doi-asserted-by":"crossref","first-page":"S1707","DOI":"10.1016\/j.annonc.2025.09.060","article-title":"LBA48 BURAN: a phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)","volume":"36","author":"Soulieres","year":"2025","journal-title":"Ann. Oncol."},{"issue":"46","key":"10.1016\/j.critrevonc.2026.105207_bib91","doi-asserted-by":"crossref","first-page":"76087","DOI":"10.18632\/oncotarget.12590","article-title":"Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma","volume":"7","author":"Stanam","year":"2016","journal-title":"Oncotarget"},{"issue":"6046","key":"10.1016\/j.critrevonc.2026.105207_bib92","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105207_bib93","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.2006.06.6605","article-title":"Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer","volume":"25","author":"Temam","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105207_bib94","doi-asserted-by":"crossref","first-page":"32668","DOI":"10.18632\/oncotarget.15949","article-title":"Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation","volume":"8","author":"Thomas Koch","year":"2017","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105207_bib95","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1158\/1078-0432.CCR-10-3338","article-title":"Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment","volume":"17","author":"Tinhofer","year":"2011","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib96","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41467-025-56675-3","article-title":"PPAR\u03b1-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma","volume":"16","author":"Van den Bossche","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105207_bib97","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.6024","article-title":"Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent\/metastatic (r\/m) head and neck squamous cell carcinoma (HNSCC): phase 2 trial","volume":"43","author":"van Herpen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105207_bib98","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2147\/OTT.S132187","article-title":"Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma","volume":"10","author":"Vatte","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105207_bib99","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"Vermorken","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105207_bib100","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105207_bib101","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","article-title":"SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial","volume":"14","author":"Vermorken","year":"2013","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105207_bib102","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neo.2014.03.004","article-title":"Cetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance","volume":"16","author":"Weinandy","year":"2014","journal-title":"Neoplasia"},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105207_bib103","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1038\/onc.2008.19","article-title":"Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members","volume":"27","author":"Wheeler","year":"2008","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105207_bib104","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-11-1593","article-title":"Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma","volume":"18","author":"Wheeler","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbrc.2019.06.159","article-title":"Differential escape mechanisms in cetuximab-resistant head and neck cancer cells","volume":"517","author":"Willey","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105207_bib106","first-page":"15","article-title":"Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer","volume":"26","author":"Wilson","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105207_bib107","doi-asserted-by":"crossref","first-page":"S590","DOI":"10.1016\/j.annonc.2023.09.2083","article-title":"939P Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients","volume":"34","author":"Xue","year":"2023","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105207_bib108","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.cell.2007.11.013","article-title":"SnapShot: EGFR signaling pathway","volume":"131","author":"Yarden","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105207_bib109","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canlet.2021.03.013","article-title":"Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition","volume":"507","author":"You","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105207_bib110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mam.2015.07.001","article-title":"Targeting HER (ERBB) signaling in head and neck cancer: an essential update","volume":"45","author":"Zhang","year":"2015","journal-title":"Mol. Asp. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105207_bib111","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/annonc\/mdz020","article-title":"Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial","volume":"30","author":"Zhao","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105207_bib112","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jso.23406","article-title":"Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis","volume":"108","author":"Zhu","year":"2013","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105207_bib113","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12916-025-04103-0","article-title":"Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial","volume":"23","author":"Zou","year":"2025","journal-title":"BMC Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:54:04Z","timestamp":1775908444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":113,"alternative-id":["S1040842826000946"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105207","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105207"}}